10:36 AM EST, 01/15/2025 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Wednesday it received the independent ethics board approval to initiate a human pilot study to compare an oral version of liraglutide with the conventional injected method.

The company said the oral version is formulated using DehydraTECH-processing and the pilot study will focus on safety and pharmacokinetic performance in humans.

Novo Nordisk markets liraglutide's injectable form as Saxenda and Victoza for weight loss and treatment of diabetes.

Shares of Lexaria were up over 6% in recent trading.

Price: 2.06, Change: +0.13, Percent Change: +6.94